A Comprehensive Molecular and Clinical Investigation of Approved Anti-HCV Drugs Repurposing against SARS-CoV-2 Infection: A Glaring Gap between Benchside and Bedside Medicine

The limited availability of effective treatment against SARS-CoV-2 infection is a major challenge in managing COVID-19. This scenario has augmented the need for repurposing anti-virals for COVID-19 mitigation. In this report, the anti-SARS-CoV-2 potential of anti-HCV drugs such as daclatasvir (DCV)...

Descripción completa

Detalles Bibliográficos
Autores principales: Bansode, Sneha, Singh, Pawan Kumar, Tellis, Meenakshi, Chugh, Anita, Deshmukh, Narendra, Gupta, Mahesh, Verma, Savita, Giri, Ashok, Kulkarni, Mahesh, Joshi, Rakesh, Chaudhary, Dhruva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056950/
https://www.ncbi.nlm.nih.gov/pubmed/36992099
http://dx.doi.org/10.3390/vaccines11030515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056950/
https://www.ncbi.nlm.nih.gov/pubmed/36992099
http://dx.doi.org/10.3390/vaccines11030515

Ejemplares similares